In TCGA, 16 out of 32 cancer histologies have tumor samples bearing protein-altering TREX1 variants, with bladder cancer and melanoma having the highest frequency of TREX1 variants at 2.7% of tumor samples (Tables S13 and S14; Fig. 4). This evidence concerns the gene TREX1 and cancer.